Equities analysts expect vTv Therapeutics Inc (NASDAQ:VTVT) to post earnings of ($0.10) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for vTv Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.06). vTv Therapeutics also posted earnings of ($0.10) per share in the same quarter last year. The firm is expected to issue its next earnings report on Wednesday, February 26th.
According to Zacks, analysts expect that vTv Therapeutics will report full year earnings of ($0.44) per share for the current financial year. For the next year, analysts expect that the company will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.55) to ($0.25). Zacks’ earnings per share averages are an average based on a survey of research firms that follow vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $1.69 million.
Shares of NASDAQ VTVT traded up $0.02 during mid-day trading on Thursday, reaching $1.55. 58,306 shares of the company traded hands, compared to its average volume of 708,035. vTv Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $3.50. The firm has a market cap of $84.99 million, a PE ratio of -2.25 and a beta of -3.61. The stock has a fifty day simple moving average of $1.47 and a 200-day simple moving average of $1.46.
In related news, major shareholder Ronald O. Perelman bought 1,369,863 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was bought at an average price of $1.46 per share, with a total value of $1,999,999.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Ronald O. Perelman bought 50,000 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were bought at an average cost of $1.38 per share, with a total value of $69,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 4,770,650 shares of company stock worth $7,077,251. 1.70% of the stock is currently owned by company insiders.
A hedge fund recently bought a new stake in vTv Therapeutics stock. Wedbush Securities Inc. bought a new stake in shares of vTv Therapeutics Inc (NASDAQ:VTVT) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 25,100 shares of the biotechnology company’s stock, valued at approximately $39,000. Institutional investors own 6.12% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Further Reading: How to invest using market indexes
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.